Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant interferon treatment in human osteosarcoma

H Strander, H C Bauer, O Brosjö

    Cancer Treatment and Research
    |January 1, 1993
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The blood-tendon barrier: identification and characterisation of a novel tissue barrier in tendon blood vessels.

    European cells & materials·2016
    Same author

    Association of laminin and other basement membrane components with regions of high acetylcholine receptor density on cultured myotubes.

    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·2014
    Same author

    Lack of mutation at codon 12 of the C-h-ras oncogene in 51 human sarcomas assessed by PCR-rflp.

    International journal of oncology·2011
    Same author

    Nonrandom secondary chromosome-aberrations in synovial sarcomas with t(x-18).

    International journal of oncology·2011
    Same author

    New aspects of the molecular constituents of tissue barriers.

    Journal of neural transmission (Vienna, Austria : 1996)·2010
    Same author

    The dual role of zonula occludens (ZO) proteins.

    Journal of biomedicine & biotechnology·2010

    This study compared natural interferon (IFN) alpha, chemotherapy, and no adjuvant treatment for osteosarcoma. Chemotherapy showed slightly better survival than IFN, but neither significantly improved outcomes compared to no adjuvant therapy.

    Area of Science:

    • Oncology
    • Immunotherapy
    • Adjuvant Therapy

    Background:

    • Osteosarcoma is a rare bone cancer often treated with adjuvant therapies to improve survival rates.
    • Interferon (IFN) alpha has been explored as an immunotherapeutic agent in various cancers, including osteosarcoma.
    • Previous adjuvant trials have investigated the efficacy of different treatment modalities in osteosarcoma management.

    Purpose of the Study:

    • To present an updated analysis of an adjuvant trial for osteosarcoma in Sweden.
    • To compare the efficacy of natural interferon (IFN) alpha versus high-dose chemotherapy and a nonadjuvant control group.
    • To evaluate the overall survival rates associated with each treatment arm.

    Main Methods:

    • A prospective adjuvant trial was conducted in Sweden involving osteosarcoma patients.

    Related Experiment Videos

  • Patients were assigned to receive either natural interferon (IFN) alpha, high-dose chemotherapy, or no adjuvant treatment.
  • Overall survival was the primary endpoint assessed for each treatment group.

    • Main Results:

    • Overall survival rates were 49% for the IFN group, 54% for the chemotherapy group, and 35% for the nonadjuvant group.
    • The high-dose chemotherapy group demonstrated a slightly higher overall survival compared to the IFN group.
    • Evaluation of trial results was complicated by pre-existing differences in clinicopathologic features between the groups.

    Conclusions:

    • The role of natural interferon (IFN) alpha in the adjuvant treatment of osteosarcoma remains undetermined based on this trial.
    • While chemotherapy showed a trend towards improved survival, the definitive benefit of adjuvant therapy requires further investigation.
    • Differences in prognostic factors among treatment groups limit the ability to establish clear treatment efficacy.